{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:41Z","timestamp":1786119461993,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1097\/mca.0b013e3283349cd7","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T05:30:33Z","timestamp":1274938233000},"page":"286-291","source":"Crossref","is-referenced-by-count":1,"title":["Valproic acid inhibits proliferation of human coronary vascular cells (SI\/MPL-ratio: 0.5): a novel candidate for systemic and local therapy of postinterventional restenosis"],"prefix":"10.1097","volume":"21","author":[{"given":"Rainer","family":"Voisard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regine","family":"Baur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinzenz","family":"Hombach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210204","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2174\/0929867023369763","article-title":"Valproate and valproate-analogues: potent tools to fight against cancer","volume":"9","author":"Blaheta","year":"2002","journal-title":"Curr Med Chem"},{"key":"R2-6-20210204","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.2006.08.6165","article-title":"Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitior epirubicin in advanced soild tumors: a clinical and translational study","volume":"25","author":"Munster","year":"2007","journal-title":"J Clin Oncol"},{"key":"R3-6-20210204","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ctrv.2007.11.003","article-title":"Valproic acid as epigenetic cancer drug, preclinical, clinical and transcriptional effects on solid tumor","volume":"34","author":"Duenas-Gonzalez","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"R4-6-20210204","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/01.ATV.10.1.62","article-title":"Growth characteristics and cytoskeletal organization of cultured smooth muscle cells from human primary stenosing and restenosing lesions","volume":"10","author":"Dartsch","year":"1990","journal-title":"Arteriosclerosis"},{"key":"R5-6-20210204","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1161\/01.CIR.85.2.554","article-title":"Migratory activity of human smooth muscle cells culivated from coronary and peripheral primary and restenotic lesions removed by percutaneous atherectomy","volume":"85","author":"Bauriedel","year":"1992","journal-title":"Circulation"},{"key":"R6-6-20210204","first-page":"186","article-title":"Two decades of failing systemic restenosis trials: clinical relevance of positive in vitro data","volume":"17","author":"Voisard","year":"2004","journal-title":"Perfusion"},{"key":"R7-6-20210204","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/00019501-199310000-00014","article-title":"The in-vitro effect of antineoplastic agents on proliferative activity and cytoskeletal components of plaque-derived smooth-muscle cells from human coronary arteries","volume":"4","author":"Voisard","year":"1993","journal-title":"Coron Artery Dis"},{"key":"R8-6-20210204","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2174\/138920008784892119","article-title":"Drug eluting stents: friends or foe? A review of cellular mechanisms behind the effects of Paclitaxel and sirolimus elutings stents","volume":"9","author":"Chatterjee","year":"2008","journal-title":"Curr Drug Metab"},{"key":"R9-6-20210204","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2261-7-15","article-title":"Sirolimus inhibits key events of restenosis in vitro\/ex vivo: evaluation of the clinical relevance of the data by SI\/MPL- and SI\/DES-ratios","volume":"7","author":"Voisard","year":"2007","journal-title":"BMC Cardiovasc Disord"},{"key":"R10-6-20210204","first-page":"2845","article-title":"Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria","volume":"71","author":"Jaffe","year":"1973","journal-title":"J Clin Invest"},{"key":"R11-6-20210204","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00007691-199906000-00005","article-title":"Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion","volume":"21","author":"Franssen","year":"1999","journal-title":"Ther drug Monit"},{"key":"R12-6-20210204","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00019501-199703000-00011","article-title":"High dose diltiazem prevents migration and proliferation of vascular smooth muscle cells in various in-vitro models of human coronary restenosis","volume":"8","author":"Voisard","year":"1997","journal-title":"Coron Artery Dis"},{"key":"R13-6-20210204","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0167-5273(94)90206-2","article-title":"Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro","volume":"43","author":"Voisard","year":"1994","journal-title":"Int J Cardiol"},{"key":"R14-6-20210204","first-page":"347","article-title":"Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro","volume":"21","author":"Kn\u00fcpfer","year":"2001","journal-title":"Antican Res"},{"key":"R15-6-20210204","first-page":"1","article-title":"The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in in vivo","volume":"12","author":"Jones","year":"2008","journal-title":"J Cell Mol Med"},{"key":"R16-6-20210204","first-page":"293","article-title":"Modulation of adhesion and growth of colon and pancreatic cancer cells by histone deacetylase inhibitor valproic acid","volume":"22","author":"Jones","year":"2008","journal-title":"Int J Mol Med"},{"key":"R17-6-20210204","first-page":"12","article-title":"Invasion assays","volume":"12","author":"Kleinman","year":"2001","journal-title":"Curr Protoc Cell Biol"},{"key":"R18-6-20210204","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00001622-200111000-00010","article-title":"Histone deacetylase inhibitors as new cancer drugs","volume":"13","author":"Marks","year":"2001","journal-title":"Curr Opinion Oncol"},{"key":"R19-6-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00001813-200201000-00001","article-title":"Histone deactelyse inhibitors in cancer treatment","volume":"12","author":"Vigushin","year":"2002","journal-title":"Anticancer Drugs"},{"key":"R20-6-20210204","first-page":"30","article-title":"Histone deacetylase inhibitors in cancer therapy","volume":"2","author":"Rosato","year":"2003","journal-title":"Cancer Biol Therap"},{"key":"R21-6-20210204","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1158\/0008-5472.CAN-04-2478","article-title":"Valproic acid alters chromatin structure by regulation of chromatin modulation proteins","volume":"65","author":"Marchion","year":"2005","journal-title":"Cancer Res"},{"key":"R22-6-20210204","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1677\/joe.1.06970","article-title":"Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells","volume":"191","author":"Catalano","year":"2006","journal-title":"J Endocrinol"},{"key":"R23-6-20210204","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1677\/ERC-07-0096","article-title":"Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines","volume":"14","author":"Catalano","year":"2007","journal-title":"Endocr Relat Cancer"},{"key":"R24-6-20210204","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","article-title":"Valproic acid induces p21 and topoisomerase-II (alpha\/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines","volume":"85","author":"Das","year":"2007","journal-title":"J Neurooncol"},{"key":"R25-6-20210204","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijcard.2004.05.039","article-title":"Antiproliferative profile of sirolimus and mycophenolate mofetil: impact of the S\/MPL-ratio","volume":"102","author":"Voisard","year":"2005","journal-title":"Int J Cardiol"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCA.0b013e3283349cd7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:21:12Z","timestamp":1786040472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00019501-201008000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0b013e3283349cd7","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}